References
- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.
- Mandal A, Gote V, Pal D, Ogundele A, Mitra AK. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (CEQUA®) for dry eye disease. Pharm Res. 2019;36:36.
- Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510.
- Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539–74.
- Yavuz B, Bozdag Pehlivan S, Unlu N. An overview on dry eye treatment: approaches for cyclosporin a delivery. Sci World J. 2012:194848.
- Jerkins GW, Pattar GR, Kannarr SR. A review of topical cyclosporine a formulations-a disease-modifying agent for keratoconjunctivitis sicca. Clin Ophthalmol. 2020;14:481–89.
- Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014;6(5):422–37.
- Tauber J, Schechter BA, Bacharach J, Toyos MM, Smyth-Medina R, Weiss SL, Luchs JI. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921–29.
- Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126:1230–37.
- Smyth-Medina R, Johnston J, Devries DK, Jasper A, Kannarr SR, Schechter BA, Shen Lee B, Varghese G, Ogundele A, Darby CH, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on conjunctival staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and 3 clinical trials. J Ocul Pharmacol Ther. 2019;35(7):388–94.
- Sheppard J, Kannarr S, Luchs J, Malhotra R, Justice A, Ogundele A, Darby C, Bacharach J. Efficacy and safety of OTX-101, a novel nanomicellar formulation of cyclosporine a, for the treatment of keratoconjunctivitis sicca: pooled analysis of a phase 2b/3 and phase 3 study. Eye Contact Lens. 2020;46(Suppl 1):S14–S19.
- Malhotra R, Devries DK, Luchs J, Kabat A, Schechter BA, Shen Lee B, Shettle L, Smyth-Medina R, Ogundele A, Darby C, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine a, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and phase 3 studies. Cornea. 2019;38(10):1259–65.
- Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, de Paiva CS, Gomes JAP, Hammitt KM, Jones L, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–12.
- Wood SI, Mian SD. Diagnostic tools for dry eye disease. Eur Ophthalmic Rev. 2016;10(2):101-7.